{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-007717","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.863350+00:00","generated_at":"2026-06-18T03:20:57.089725+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cogent Biosciences reports FY2022 net loss $140.2M, cash $259.3M; outlines bezuclastinib milestones for 2023","bullets":["Net loss $39.6M Q4, $140.2M FY2022 vs $72.3M FY2021; R&D expenses $121.6M FY2022.","Cash, equivalents and marketable securities $259.3M as of Dec 31, 2022; runway into 2025.","APEX Part 2 initiation planned mid-2023; updated Phase 3 PEAK lead-in data expected 1H23.","Initial SUMMIT Phase 2 data in nonadvanced systemic mastocytosis expected 2H23.","Appointed Rachael Easton, M.D., Ph.D., VP Head of Clinical Development; Sylvia Adams to SAB."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-007717","json":"https://secwatch.observer/filing/0000950170-23-007717.json","markdown":"https://secwatch.observer/filing/0000950170-23-007717.md","text":"https://secwatch.observer/filing/0000950170-23-007717.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/0000950170-23-007717-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/cogt-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:20:57.089725+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54530f22ea833d94ec69bf690b8822e55a0a9957","claim":"Cogent Biosciences, Inc. reported financial results for the fourth quarter and full year of 2022.","evidence_excerpt":"On March 14, 2023, Cogent Biosciences, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023007717/0000950170-23-007717-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}